A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.

Trial Details

NCT ID
NCT06954961
Phase
PHASE3
Sponsor
InventisBio Co., Ltd
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • D-0502
  • Fulvestrant
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Harbin, Heilongjiang, China|45.75,126.65

Key Eligibility Criteria

  • Subjects pathologically confirmed with ER-positive, HER2-negative breast cancer;
  • Subjects with locally advanced (unresectable) or metastatic breast cancer who have disease recurrence during or after adjuvant endocrine therapy, o…
  • Presence of at least 1 measurable lesion that can be measured by CT or MRI based on RECIST V1.1 criteria; in the absence of measurable lesions, sub…
  • Expected survival time ≥ 12 weeks;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →